Director shareholdings

RNS Number : 0872R

Advanced Medical Solutions Grp PLC

24 April 2009

 



For Immediate release

24 April 2009

Advanced Medical Solutions Group PLC 

('AMS' or the 'Company')

Directors' shareholdings

Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, announces that the following Directors purchased ordinary shares of 5 pence each ('Ordinary Shares') on 23 April 2009, as part of the Deferred Share Bonus Plan. These Ordinary Shares were bought at a price of 34 pence per share and, under the terms of the Plan, will be held in trust on their behalf.

Director	Shares purchased	Resultant holding	% of issued share capital
Don Evans, Chief Executive Officer	55,882	849,591	0.59
Mary Tavener, Finance Director	37,352	221,130	0.15
Chris Meredith, Commercial Director	37,352	111,890	0.08

In addition, the Board granted new share options to the Directors under the Advanced Medical Solutions Long Term Incentive Plan (the 'LTIP') on 23 April 2009. These options are subject to certain performance criteria over a three year period to vest.

Director	LTIPs granted	Resultant holding
Don Evans	293,843	3,295,016
Mary Tavener	193,408	2,407,979
Chris Meredith	589,234	1,797,234

For further information, please contact:

Advanced Medical Solutions Group plc Don Evans, Chief Executive Officer Mary Tavener, Finance Director www.admedsol.com	Tel: [phone]
Buchanan Communications Mark Court  Stasa Filiplic	Tel: [phone]
Investec Bank plc Richard Jones Tim Pratelli	Tel: [phone]

Notes to Editors:

Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.  

The advanced woundcare products are based on the moist wound healing principle. AMS uses its inhouse technology to provide a vertically integrated 'one stop shop' for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

The acquisition of a 49.4% stake in Corpura BV in May 2008 strengthened AMS's position in hydrophilic polyurethane foam - the largest and fastest growing segment of the advanced woundcare market.

AMS' technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection. 

AMS' products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors. 

 

END

 

 

RDSCKNKPABKDBQB